Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC50095 EGFR-IN-34
EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12).
More description
DC50094 BTK-IN-7
BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels(ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity.
More description
DC50089 BLK-IN-1
BLK-IN-1 (compound 1) is a selective and covalent inhibitor of B-Lymphoid tyrosine kinase (BLK) and BTK, with IC50s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer.
More description
DC50086 Safingol
Safingol is a lyso-sphingolipid PKC (protein kinase C ) inhibitor.
More description
DC50084 Mongersen
Mongersen is a 21-mer phosphorothioate antisense oligonucleotide targeting the mRNA of the Smad7 protein, thus leading to suppression of TGF-β1 pathways and remission of Crohn's disease.
More description
DC50083 KRAS G12D inhibitor 14
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D.
More description
DC50082 K20
K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.
More description
DC50081 KRAS inhibitor-11
KRAS inhibitor-11 (compound 12) is a KRAS inhibitor.
More description
DC50080 KRAS G12C inhibitor 29
KRAS G12C inhibitor 29 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer.
More description
DC50054 Viridin
Viridin is a secondary metabolite and naturally occurring furanosteroid. Viridin is potent inhibitor of the lipid kinase PI3K.
More description
DC50050 PI3Kδ/γ-IN-1
PI3Kδ/γ-IN-1 is a potent, selective PI3K-δ/γ inhibitor for treatment of hematological malignancies.
More description
DC50049 PI3K-IN-26
PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1).
More description
DC50048 10Z-Hymenialdisine
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.
More description
DC50047 AKT-IN-10
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4).
More description
DC50046 AKT-IN-9
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1).
More description
DC50045 Deoxybrevianamide E
Deoxybrevianamide E, an indole alkaloid, is a biosynthetic precursor for advanced metabolites isolated from the marine-derived Aspergillus sp..
More description
DC50043 Agistatin E
Agistatin E is a pyranacetal originally isolated from a Fusarium sp. that inhibits the cholesterol biosynthesis.
More description
DC50042 Agistatin B
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits cholesterol synthesis.
More description
DC50041 Glucosylceramide synthase-IN-3
Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research.
More description
DC50037 Anti-inflammatory agent 13
Anti-inflammatory agent 13 (Compound 3) is a pentacyclic triterpene compound. Anti-inflammatory agent 13 exhibits a considerable inhibitory effect on inflammation models. Anti-inflammatory agent 13 has the potential for the research of either DAMPs or PAMPs triggered inflammation.
More description
DC50034 Anticancer agent 35
Anticancer agent 35 (compound 10), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 35 inhibits A549, A431, PACA2 cell growth with IC50s of 18.1 µg/mL, 4.0 µg/mL, 18.9 µg/mL, respectively.
More description
DC50033 Antitumor agent-46
Antitumor agent-46 (Compound 2h) is an anti-tumor agent. Antitumor agent-46 demonstrates markedly higher antiproliferative activity on MCF-7 cells with an IC50 value of 2.08 µM.
More description
DC50031 Antimalarial agent 9
Antimalarial agent 9 (Compound 11) is a potent antimalarial agent. Antimalarial agent 9 is a quinoline-imidazole derivative compound. Antimalarial agent 9 exhibits significant antimalarial efficacy in-vitro against both CQ-sensitive (IC50-0.14 μM) and MDR strain (IC50-0.41 μM) with minimal cytotoxicity and high selectivity.
More description
DC50029 Antitumor agent-48
Antitumor agent-48 (Compound 4a) is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively.
More description
DC50024 NCGC00538431
NCGC00538431 is a potent modulator of SIRPα-CD47.
More description
DC50019 AhR agonist 2
AhR agonist 2 (Compound 12a) is a potent agonist of aryl hydrocarbon receptor (AhR) with an EC50 of 0.03 nM. AhR agonist 2 induces rapid nuclear enrichment of AhR, triggers the transcription of downstream genes and promote skin barrier repair. AhR agonist 2 has the potential for the research of psoriasis.
More description
DC50018 Mitochondria-Targeted Photoactivatable Prodrug
Mitochondria-Targeted Photoactivatable Prodrug accumulates in the mitochondria and shows light-triggered temporally controlled cell death. Mitochondria-Targeted Photoactivatable Prodrug can be used in a novel drug delivery platform that provides on-demand, real-time, organelle-specific drug release and monitoring upon photoactivation.
More description
DC50017 SK-3-91
SK-3-91 is a multi-kinase degrader. SK-3-91 could collectively induce degradation of the largest number of unique kinases (>125 unique kinases).
More description
DC50016 WH-10417-099
WH-10417-099 is a degrader that could collectively induce degradation of the largest number of unique kinases (>125 unique kinases).
More description
DC50015 2-Hydroxyestradiol-13C6
2-Hydroxyestradiol-13C6 is the 13C-labeled 2-Hydroxyestradiol. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X